How Clay Siegall’s Research Work has Bettered Cancer Treatment

Clay Siegall is a biotechnology expert who has significantly impacted the pharmaceutical sector. He is the founder of a reputable research hub that is known as Seattle Genetics. Siegall has been running the enterprise since 1998, and he serves as its president, chairman, and CEO. His administration skills have assisted the firm to attain success. One of the major accomplishments of the corporation is the development of the FDA-certified therapies that have revolutionized cancer treatment.


Dr. Siegall has also committed himself to ensuring that the firm has sufficient resources to make its research undertakings successful. The enterprise had its IPO in 2001, and it has used both private and public funding to secure more than $670 million. He was employed by various research corporations before partnering with other scientists to establish Seattle Genetics. In 1991, he was hired as a lead researcher at Bristol-Myers Squib Pharmaceutical Research Institute and stayed at the firm up to 1997. Clay Siegall once served a government-owned foundation that was called National Cancer Institute. Biomedical Association and Washington Biotechnology appointed him to act as a member of their boards. He currently works as a member of Alder BioPharmaceuticals’ board of directors.


The research undertakings of Dr. Siegall have had a great impact on the pharmaceutical sector, and he has 15 patents. The science expert also owns more than 70 publications that are useful in academic and professional reference. He attended the University of Maryland for his zoology degree and also graduated from the George Washington University with a Ph.D. in genetics. Seattle Genetics has managed to develop effective ADCs that have improved cancer treatment. The technology is outstanding, and more than 21 drugs have been manufactured by using it. The company now sells its medicine in the United States and other regions of the world.


The global distribution of the company’s drugs has been facilitated by collaborations with enterprises such as Takeda Pharmaceutical Company. Seattle Genetics manufactures SGN-40 by partnering with a firm that is known as Genentech. The venture that is conducted by the two companies is worth over $860 million. Seattle has been striving to offer the world the best treatment for cancer.